

=> d his

(FILE 'HOME' ENTERED AT 10:18:02 ON 11 SEP 2006)

FILE 'REGISTRY' ENTERED AT 10:18:12 ON 11 SEP 2006

L1	STRUCTURE UPLOADED
L2	0 S L1 FAM SAM
L3	10 S L1 FAM FULL
L4	STRUCTURE UPLOADED
L5	0 S L4 FAM SAM
L6	1 S L4 FAM FULL
L7	STRUCTURE UPLOADED
L8	1 S L6 FAM FULL
L9	2 S L7 FAM FULL

FILE 'CAPLUS' ENTERED AT 10:21:47 ON 11 SEP 2006

L10	6 S L2/THU OR L6/THU OR L9/THU
L11	9 S L2 OR L6 OR L9
L12	2 S L11 AND (PARKINSON? OR TREMOR)
L13	2 S L11 AND DYSTONIA

=>

=>
Uploading C:\Program Files\Stnexp\Queries\10735514diphenyl.str

L1 STRUCTURE UPLOADED

=> d l12


L12 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam sam

SAMPLE SEARCH INITIATED 10:18:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA FAM SAM L1

=> s l1 fam full

FULL SEARCH INITIATED 10:18:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 70 TO ITERATE

100.0% PROCESSED 70 ITERATIONS


10 ANSWERS

SEARCH TIME: 00.00.01

L3 10 SEA FAM FUL L1

=> d l3 scan


L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, monolithium salt (9CI)
 MF C16 H12 N2 O3 . Li



● Li

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, potassium salt (9CI)
 MF C16 H12 N2 O3 . x K




●x K

L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, compd. with
 N,N'-bis(1,1-dimethylethyl)-1,3,5-triazine-2,4,6-triamine (1:1) (9CI)
 MF C16 H12 N2 O3 . C11 H22 N6

CM 1




CM 2




L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzeneacetamide, N-(aminocarbonyl)-, mixt. with 5,5-diphenyl-2,4-imidazolidinedione and 5,5-diphenyl-2,4,6(1H,3H,5H)-pyrimidinetrione (9CI)
 MF C16 H12 N2 O3 . C15 H12 N2 O2 . C9 H10 N2 O2
 CI MXS


CM 1




CM 2



CM 3



L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, lithium salt (9CI)
 MF C16 H12 N2 O3 . x Li




●x Li


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, compd. with
 9-ethyl-9H-purin-6-amine (1:1) (9CI)
 MF C16 H12 N2 O3 . C7 H9 N5


CM 1



CM 2




L3 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl- (9CI)
 MF C16 H12 N2 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 10 ANSWERS . REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, monopotassium salt (9CI)
MF C16 H12 N2 O3 . K



● K

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>


Uploading C:\Program Files\Stnexp\Queries\10735514diphenyl2b.str

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 fam sam

SAMPLE SEARCH INITIATED 10:19:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA FAM SAM L4


=> s l4 fam full
FULL SEARCH INITIATED 10:20:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L6 1 SEA FAM FUL L4

=> d l6 1 scan
'1' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L6 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(methoxymethyl)-5,5-diphenyl-
(9CI)
MF C20 H20 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.


The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.

=> d 16 scan

L6 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(methoxymethyl)-5,5-diphenyl-
(9CI)
MF C20 H20 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\Stnexp\Queries\10735514diphenyl3.str

L7 STRUCTURE UPLOADED

```
=> d 16 fam full
'FAM' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'FULL' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG      - RN
SAM      - Index Name, MF, and structure - no RN
FIDE     - All substance data, except sequence data
IDE      - FIDE, but only 50 names
SQIDE    - IDE, plus sequence data
SQIDE3   - Same as SQIDE, but 3-letter amino acid codes are used
SQD      - Protein sequence data, includes RN
SQD3     - Same as SQD, but 3-letter amino acid codes are used
SQN      - Protein sequence name information, includes RN

CALC     - Table of calculated properties
EPROP    - Table of experimental properties
PROP     - EPROP and CALC
```

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

```
ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations
```

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

```
HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):ti
'TI' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.


The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):
ENTER DISPLAY FORMAT (IDE):ide

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 97846-21-4 REGISTRY
ED Entered STN: 31 Aug 1985
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(methoxymethyl)-5,5-diphenyl-
(9CI) (CA INDEX NAME)
FS 3D CONCORD

MF C20 H20 N2 O5
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s 16 fam full
 FULL SEARCH INITIATED 10:20:49 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

L8 1 SEA FAM FUL L4

=> d 18 scan

L8 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(methoxymethyl)-5,5-diphenyl-
 (9CI)
 MF C20 H20 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED


=> s 17 fam full
 FULL SEARCH INITIATED 10:21:31 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 2 ANSWERS
 SEARCH TIME: 00.00.01

L9 2 SEA FAM FUL L7

=> d 19 scan


L9 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(methoxymethyl)-5,5-diphenyl- (9CI)
MF C18 H16 N2 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(methoxymethyl)-5,5-diphenyl-, sodium
salt (9CI)
MF C18 H16 N2 O4 . Na



● Na

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
265.54	265.75

FILE 'CAPLUS' ENTERED AT 10:21:47 ON 11 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 10 Sep 2006 (20060910/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L2/thu or l6/thu or l9/thu

0 L2

809336 THU/RL

0 L2/THU

(L2 (L) THU/RL)

7 L6

809336 THU/RL

4 L6/THU

(L6 (L) THU/RL)

7 L9

809336 THU/RL

5 L9/THU

(L9 (L) THU/RL)

L10 6 L2/THU OR L6/THU OR L9/THU

=> s l2 or l6 or l9

0 L2

7 L6

7 L9

L11 9 L2 OR L6 OR L9

=> s l11 and (parkinson? or tremor)

24531 PARKINSON?

4202 TREMOR

L12 2 L11 AND (PARKINSON? OR TREMOR)

=> d l12 1-2 ti

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of treating movement disorders using barbituric acid derivatives

=> s l11 and dystonia

1475 DYSTONIA

L13 2 L11 AND DYSTONIA

=> d l13 1-2 ti

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of treating movement disorders using barbituric acid derivatives

=> d 113 1-2 ti abs bib

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

AB The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurol. conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-di-Ph barbituric acid (I) to enhance the bioavailability of 5,5-di-Ph barbituric acid and brain delivery of same. I was prepared by the reaction of 5,5-di-Ph barbituric acid with sodium hydroxide. Oral administration of 75 mg/kg I increased the bioavailability of 75 mg/kg 5,5-di-Ph barbituric acid in dogs.

AN 2006:142534 CAPLUS

DN 144:219186

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

IN Levitt, Barrie; Moros, Daniel; Yacobi, Avraham; Gutman, Daniella

PA Taro Pharmaceuticals North America, Inc., Cayman I.

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1625848	A1	20060215	EP 2005-290804	20050412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	WO 2006026095	A2	20060309	WO 2005-US28380	20050810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-600327P	P	20040810		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of treating movement disorders using barbituric acid derivatives
GI



AB A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound I [R3, R4 = lower alkyl, Ph, lower alkyl-substituted Ph; R1, R2 = H, CH(R6)OCH2R5 (R5, R6 = H, lower alkyl, Ph, lower alkyl-substituted Ph)] and pharmaceutically acceptable salts, prodrugs, and metabolites thereof. Preparation of monomethoxymethyldiphenylbarbituric acid is described.

AN 2004:513524 CAPLUS

DN 141:47363

TI Method of treating movement disorders using barbituric acid derivatives

IN Moros, Daniel Aaron

PA Taro Pharmaceuticals Ireland Limited, Ire.

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052350	A2	20040624	WO 2003-US39530	20031211
	WO 2004052350	A3	20040923		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2505335	AA	20040624	CA 2003-2505335	20031211
	AU 2003302897	A1	20040630	AU 2003-302897	20031211
	EP 1569627	A2	20050907	EP 2003-812970	20031211
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017289	A	20051108	BR 2003-17289	20031211
	CN 1717235	A	20060104	CN 2003-80104405	20031211
	JP 2006510659	T2	20060330	JP 2004-558727	20031211
PRAI	US 2002-432470P	P	20021211		
	WO 2003-US39530	W	20031211		
OS	MARPAT 141:47363				

=> d l11 1-9 ti

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Process for N-alkoxyalkylation of ureides with alkoxyalkyl sulfonates with amine or hydride bases

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Catalytic dealkylation process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid from 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric acid using a Lewis acid

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Method of treating movement disorders using barbituric acid derivatives

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Non-sedating barbiturate compounds as neuroprotective agents

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI N-alkoxyalkylation of ureides.

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Oxopyrimidine derivatives and pharmaceutical compositions containing them

=> d l11 1 2 5 6 9 ti abs bib

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

AB The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurol. conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-di-Ph barbituric acid to enhance the bioavailability of 5,5-di-Ph barbituric acid and brain delivery of same. Thus, 5,5-di-Ph barbituric acid (DPB) was dissolved in 1,500 mL THF. The turbid solution was filtered through folded filter paper. Sodium hydroxide solution was prepared by dissolving in a mixture of 150 mL THF and 25 mL water. The sodium hydroxide solution was added dropwise to the DPB solution over a period of 0.5 h. The sodium salt of DPB formed and precipitated from the solution Sodium salt of

DPB increase bioavailability of DPB.

AN 2006:540918 CAPLUS

DN 145:34201

TI Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

IN Gutman, Daniella; Moros, Daniel; Yacobi, Avraham; Rutman, Howard

PA Israel

SO U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. Ser. No. 865,428. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006122208	A1	20060608	US 2005-201024	20050810
	WO 2002007729	A1	20020131	WO 2001-US23420	20010726
	WO 2002007729	C2	20020808		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003153589	A1	20030814	US 2003-333957	20030127
	US 6756379	B2	20040629		
	US 2003187005	A1	20031002	US 2003-354146	20030130

	US 6939873,	B2	20050906		
	US 2004186120	A1	20040923	US 2003-735514	20031211
	US 2004224947	A1	20041111	US 2004-865428	20040610
PRAI	US 2000-221672P	P	20000726		
	WO 2001-US23420	W	20010726		
	US 2002-352273P	P	20020130		
	US 2002-432470P	P	20021211		
	US 2003-333957	A1	20030127		
	US 2003-354146	A2	20030130		
	US 2003-735514	A2	20031211		
	US 2004-865428	A2	20040610		
	US 2004-600327P	P	20040810		

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

AB The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurol. conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-di-Ph barbituric acid (I) to enhance the bioavailability of 5,5-di-Ph barbituric acid and brain delivery of same. I was prepared by the reaction of 5,5-di-Ph barbituric acid with sodium hydroxide. Oral administration of 75 mg/kg I increased the bioavailability of 75 mg/kg 5,5-di-Ph barbituric acid in dogs.

AN 2006:142534 CAPLUS

DN 144:219186

TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

IN Levitt, Barrie; Moros, Daniel; Yacobi, Avraham; Gutman, Daniella

PA Taro Pharmaceuticals North America, Inc., Cayman I.

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1625848	A1	20060215	EP 2005-290804	20050412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	WO 2006026095	A2	20060309	WO 2005-US28380	20050810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-600327P P 20040810

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of treating movement disorders using barbituric acid derivatives
GI



AB A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound I [R3, R4 = lower alkyl, Ph, lower alkyl-substituted Ph; R1, R2 = H, CH(R6)OCH2R5 (R5, R6 = H, lower alkyl, Ph, lower alkyl-substituted Ph)] and pharmaceutically acceptable salts, prodrugs, and metabolites thereof. Preparation of monomethoxymethyldiphenylbarbituric acid is described.

AN 2004:513524 CAPLUS

DN 141:47363

TI Method of treating movement disorders using barbituric acid derivatives

IN Moros, Daniel Aaron

PA Taro Pharmaceuticals Ireland Limited, Ire.

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052350	A2	20040624	WO 2003-US39530	20031211
	WO 2004052350	A3	20040923		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2505335	AA	20040624	CA 2003-2505335	20031211
	AU 2003302897	A1	20040630	AU 2003-302897	20031211
	EP 1569627	A2	20050907	EP 2003-812970	20031211
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017289	A	20051108	BR 2003-17289	20031211
	CN 1717235	A	20060104	CN 2003-80104405	20031211
	JP 2006510659	T2	20060330	JP 2004-558727	20031211
PRAI	US 2002-432470P	P	20021211		
	WO 2003-US39530	W	20031211		
OS	MARPAT 141:47363				

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Non-sedating barbiturate compounds as neuroprotective agents

AB Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compds. are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death.

AN 2002:89833 CAPLUS

DN 136:129076
 TI Non-sedating barbiturate compounds as neuroprotective agents
 IN Moros, Daniel A.; Levitt, Barrie; Yacobi, Avraham
 PA Taro Pharmaceutical Industries Ltd., Israel
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007729	A1	20020131	WO 2001-US23420	20010726
	WO 2002007729	C2	20020808		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2416535	AA	20020131	CA 2001-2416535	20010726
	AU 2001080778	A5	20020205	AU 2001-80778	20010726
	EP 1311270	A1	20030521	EP 2001-959195	20010726
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012775	A	20031230	BR 2001-12775	20010726
	JP 2004517808	T2	20040617	JP 2002-513464	20010726
	US 2003153589	A1	20030814	US 2003-333957	20030127
	US 6756379	B2	20040629		
	US 2003187005	A1	20031002	US 2003-354146	20030130
	US 6939873	B2	20050906		
	US 2004224947	A1	20041111	US 2004-865428	20040610
	AU 2004229086	A1	20041202	AU 2004-229086	20041115
	US 2006035915	A1	20060216	US 2005-169044	20050628
	US 2006122208	A1	20060608	US 2005-201024	20050810
PRAI	US 2000-221672P	P	20000726		
	AU 2001-280778	A3	20010726		
	WO 2001-US23420	W	20010726		
	US 2002-352273P	P	20020130		
	US 2002-432470P	P	20021211		
	US 2003-333957	A1	20030127		
	US 2003-354146	A1	20030130		
	US 2003-735514	A2	20031211		
	US 2004-865428	A2	20040610		
	US 2004-600327P	P	20040810		

OS MARPAT 136:129076

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Oxopyrimidine derivatives and pharmaceutical compositions containing them
 GI



AB Barbiturates I [R, R1 = H, alkyl, alkoxyalkyl; R2, R3 = Ph, alkylphenyl, halophenyl] were prepared. Thus I (R = R1 = H, R2 = R3 = Ph) was treated with ClCH2OMe to give 70% I (R = R1 = CH2OMe, R2 = R3 = Ph) which at 500 mg/kg orally in rats gave 100% protection in the maximum electroshock test 23 h after administration. I (R = R1 = H, R2 = R3 = 4-MeC6H4) had tranquilizing activity at 200 mg/kg i.p.

AN 1985:487713 CAPLUS

DN 103:87713

TI Oxopyrimidine derivatives and pharmaceutical compositions containing them

IN Levitt, Barrie; Stolar, Morris

PA Taro Pharmaceutical Industries Ltd., Israel

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 137343	A2	19850417	EP 1984-110959	19840913
	EP 137343	A3	19860611		
	EP 137343	B1	19911204		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	IL 69722	A1	19860930	IL 1983-69722	19830914
	US 4628056	A	19861209	US 1984-647680	19840905
	AU 8432875	A1	19850321	AU 1984-32875	19840910
	AU 571265	B2	19880414		
	DK 8404317	A	19850315	DK 1984-4317	19840911
	DK 167615	B1	19931129		
	JP 60084272	A2	19850513	JP 1984-192413	19840913
	JP 07030044	B4	19950405		
	AT 70056	E	19911215	AT 1984-110959	19840913
	ZA 8407274	A	19860430	ZA 1984-7274	19840914
PRAI	IL 1983-69722	A	19830914		
	EP 1984-110959	A	19840913		
OS	MARPAT 103:87713				